GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects
Background
Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide.
Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotech and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect—–the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as “Special K”, ketamine, made headlines in the early 2000s. Human clinical studies demonstrated that ketamine can ward off major and bipolar depressive symptoms within 2 hours of administration and last for several days. Ketamine is fraught with serious side effects including excessive sleepiness, hallucinations, and substance abuse behavior.
“Ketamine lit the field back up,“ said Joseph Moskal, Ph.D., a molecular neurobiologist at Northwestern University and senior study author. “Our drug, GLYX-13, is very different. It does not block the receptor ion channel, which may account for why it doesn’t have the same side effects.”
Moskal’s journey with GLYX-13 came about from his earlier days as a Senior Staff Fellow in NIMH’s Intramural Research Program. While at NIMH, he created specific molecules, monoclonal antibodies, to use as new probes to understand pathways of learning and memory. Some of the antibodies he created were for NMDA receptors. When he moved to Northwestern University, Moskal converted the antibodies to small protein molecules. Comprised of only four amino acids, GLYX-13 is one of these molecules.
Previous electrophysiological and conditioning studies had suggested that GLYX-13, unlike ketamine, enhanced memory and learning in rats, particularly in the brain’s memory hub or hippocampus. GLYX-13 also produced analgesic effects. Using several rat behavioral and molecular experiments, Moskal’s research team tested four compounds: GLYX-13, an inactive, “scrambled” version of GLYX-13 that had its amino acids rearranged, ketamine, and the SSRI fluoxetine.
Results of the Study
GLYX-13 and ketamine produced rapid acting (1 hour) and long-lasting (24 hour) antidepressant-like effects in the rats. Fluoxetine, an SSRI that typically takes from 2–4 weeks to show efficacy in humans, did not produce a rapid antidepressant effect in this study. As expected, the scrambled GLYX-13 showed no antidepressant-like effects at all. The researchers observed none of the aforementioned side effects of ketamine in the GLYX-13–treated rats.
Protein studies indicated an increase in the hippocampus of the NMDA receptor NR2B and a receptor for the chemical messenger glutamate called AMPA. Electrophysiology studies in this brain region showed that GLYX-13 and ketamine promoted long-lasting signal transmission in neurons, known as long-term potentiation/synaptic plasticity. This phenomenon is essential in learning and memory. The researchers propose how GLYX-13 works: GLYX-13 triggers NR2B receptor activation that leads to intracellular calcium influx and the expression of AMPA, which then is responsible for increased communication between neurons.
These results are consistent with data from a recent Phase 2 clinical trial, in which a single administration of GLYX-13 produced statistically significant reductions in depression scores in patients who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of 7 days. After a single dose of GLYX-13, the drug’s antidepressant efficacy nearly doubled that seen with most conventional antidepressants after 4–6 weeks of dosing. GLYX-13 was well tolerated and it did not produce any of the schizophrenia-like effects associated with other NMDA receptor modulating agents.
The Latest Bing News on:
Major depression
- Is It Safe to Take Ozempic if You Have Depression?on March 28, 2024 at 1:37 pm
Experts aren’t yet sure how Ozempic affects people with depression because they were excluded from clinical trials. Here’s what we know so far.
- Candace Cameron Bure Details Her Battle With Depressionon March 28, 2024 at 8:18 am
Full House star Candace Cameron shared more about her journey with depression: “There are a lot of people who feel that it’s weak.” ...
- BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysison March 28, 2024 at 1:00 am
The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD). In the study, data was analyzed from 247 depression ...
- Depression TMS Cleared for Teens; Phase III Narcolepsy Win; Fake ADHD Diagnosis?on March 27, 2024 at 11:37 am
Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...
- Which drugs are most likely to be approved in Major Depressive Disorder?on March 27, 2024 at 11:20 am
Major Depressive Disorder disease is an indication for drug development with over 130 pipeline drugs currently active according to GlobalData.
- What Are The Complications For Depression? A Review By Doctorson March 26, 2024 at 2:28 pm
Expert opinion from Ilya Aleksandrovskiy M.D., MBA · 5 years of experience · USA Clinical depression can exacerbate the symptoms of more serious health problems such as heart disease or cancer.
- The fear of depression recurrence is potent but not universal, research showson March 26, 2024 at 2:00 pm
Clinicians treating patients who live with or survive serious diseases such as cancer are familiar with the concept of fear of illness recurrence (FIR). FIR has been associated with greater avoidance ...
- Ketamine Is Showing Increasing Promise in Treating Depression, but Major Questions Remainon March 26, 2024 at 11:35 am
Recent findings indicate a significant positive reaction among numerous patients, however, ongoing research is focusing on identifying blood biomarkers to forecast effectiveness, and to assess the ...
- Neuronetics' magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionon March 26, 2024 at 8:02 am
Neuronetics has secured a groundbreaking green light for its noninvasive transcranial magnetic stimulation technology, saying it is now the first to be cleared by the FDA as an add-on therapy for m | ...
- TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depressionon March 24, 2024 at 5:00 pm
The Food and Drug Administration (FDA) has cleared NeuroStar ® Advanced Therapy for use as an adjunct in the treatment of major depressive disorder (MDD) in patients 15 to 21 years of age. NeuroStar ...
The Latest Google Headlines on:
Major depression
[google_news title=”” keyword=”Major depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Fix the internet
- How to fix the most common Blink Mini 2 problemson March 28, 2024 at 12:30 pm
Here's a look at how to fix the most common Blink Mini 2 problems, including poor video quality, inaccurate motion detection, and red indicator LED lights.
- PDF Preview Handler Not Working in Outlook. Fix It in 8 Wayson March 28, 2024 at 9:33 am
Outlook is a widely used email service known for its, automated emails, customizable calendars, collaboration tools, and fast alerts. However, more often than not some users are faced with PDF preview ...
- Books focused on AI, the internet are finalists for first-ever Women's Nonfiction Prizeon March 28, 2024 at 8:28 am
Finalists for the inaugural Women’s Prize for Nonfiction, aimed at addressing the gender imbalance in nonfiction publishing, were unveiled on Wednesday.
- How to fix the error code Clog in Apex Legendson March 27, 2024 at 1:49 pm
The quickest fix for the error code Clog in Apex is persistently trying to connect Apex Apex’s ...
- Books on the impact of the internet and AI are finalists for the first-ever Women's Nonfiction Prizeon March 27, 2024 at 11:14 am
Books about the dizzying impact of the internet and artificial intelligence are among finalists for a new book prize that aims to help fix the gender imbalance in nonfiction publishing ...
- How to Fix the "Ethernet Doesn't Have a Valid IP Configuration" Error on Windowson March 26, 2024 at 8:00 am
There are a few reasons your ethernet may not have a valid IP configuration, but there are plenty of possible fixes.
- Why Does My Internet Keep Disconnecting? 5 Ways To Fix Iton March 25, 2024 at 1:41 pm
Let’s take a look at the top five reasons why your internet keeps disconnecting and how you can fix it. Table of Contents A reliable internet connection is essential for day-to-day life ...
- How to Fix the Warzone Mobile Login Issueon March 23, 2024 at 6:00 am
If you want to know how to fix the Warzone Mobile login issue, here we'll share all the possible methods you can deal with this problem.
- 8 Best Internet Providers of March 2024on March 21, 2024 at 8:10 pm
Discover the best internet providers for your specific needs and how to choose one based on price, speed and other essential factors.
- Internet Down Again? Here Are 5 Possible Causes and How to Fix Themon March 21, 2024 at 12:39 pm
We’ve all been there: staring at a frozen screen, asking, “Why is my internet down?” There’s always that pause, where the screen buffers then halts, and we wait, hoping that the connection comes back ...
The Latest Google Headlines on:
Fix the internet
[google_news title=”” keyword=”fix the internet” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]